We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $179M
1-Year Est. Return 63.61%
This Fund
S&P 500
This Quarter Est. Return
+3.37%
1 Year Est. Return
+63.61%
3 Year Est. Return
+260.15%
5 Year Est. Return
+585.87%
10 Year Est. Return
+8,784.38%
AUM
$179M
AUM Growth
-$859K
Cap. Flow
+$15.1M
Cap. Flow %
8.44%
Top 10 Hldgs %
58.81%
Holding
38
New
1
Increased
4
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ELTX icon
Elicio Therapeutics
ELTX
+$5.83M
2
OCUL icon
Ocular Therapeutix
OCUL
+$4.99M
3
ABVX
Abivax
ABVX
+$3.96M
4
NUVB icon
Nuvation Bio
NUVB
+$489K
5
PHAR
Pharming Group
PHAR
+$492

Top Sells

Rank Stock Value
1
CRDL
Cardiol Therapeutics
CRDL
+$135K

Sector Composition

Rank Sector Weight
1 Materials 44.99%
2 Healthcare 40.31%
3 Miscellaneous 9.9%
4 Industrials 3.79%
5 Consumer Staples 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
1
MeiraGTx Holdings
MGTX
$1.33B
$16.9M 9.42%
1,250,000
– –
PHYS icon
2
Sprott Physical Gold
PHYS
$15.9B
$11.7M 6.51%
387,055
– –
ALDX icon
3
Aldeyra Therapeutics
ALDX
$89.3M
$11.7M 6.5%
5,475,516
– –
OCUL icon
4
Ocular Therapeutix
OCUL
$2.34B
$11.3M 6.3%
1,150,400
+550,000
+92% +$4.99M
RGLD icon
5
Royal Gold
RGLD
$22.2B
$10.5M 5.87%
52,750
– –
ENTX icon
6
Entera Bio
ENTX
$519M
$10.4M 5.81%
5,881,879
– –
NUVB icon
7
Nuvation Bio
NUVB
$2.39B
$9.08M 5.06%
1,598,591
+100,000
+7% +$489K
AEM icon
8
Agnico Eagle Mines
AEM
$104B
$8.18M 4.56%
52,750
– –
SA
9
Seabridge Gold
SA
$3.43B
$8.16M 4.55%
317,003
– –
KGC icon
10
Kinross Gold
KGC
$36.6B
$7.56M 4.22%
320,000
– –
OR icon
11
OR Royalties Inc
OR
$6.99B
$7.12M 3.97%
225,000
– –
SSRM icon
12
SSR Mining
SSRM
$7.58B
$6.93M 3.86%
245,000
– –
FNV icon
13
Franco-Nevada
FNV
$51.3B
$6.67M 3.72%
32,000
– –
BAH icon
14
Booz Allen Hamilton
BAH
$8.76B
$5.69M 3.18%
13,000
– –
CGAU
15
Centerra Gold
CGAU
$4.48B
$5.69M 3.18%
359,000
– –
ELTX icon
16
Elicio Therapeutics
ELTX
$63.3M
$4.74M 2.64%
1,211,957
+581,042
+92% +$5.83M
ABVX
17
Abivax
ABVX
$10B
$4.66M 2.6%
+35,000
New +$3.96M
PAAS icon
18
Pan American Silver
PAAS
$21.3B
$4.48M 2.5%
100,035
– –
PSLV icon
19
Sprott Physical Silver Trust
PSLV
$13.7B
$4.19M 2.34%
222,160
– –
TFPM icon
20
Triple Flag Precious Metals
TFPM
$6.99B
$3.45M 1.92%
115,000
– –
ABEO icon
21
Abeona Therapeutics
ABEO
$343M
$3M 1.67%
485,515
– –
GROY icon
22
Gold Royalty Corp
GROY
$776M
$2.76M 1.54%
1,000,000
– –
NEWP
23
New Pacific Metals
NEWP
$1.15B
$1.95M 1.09%
485,000
– –
ITA icon
24
iShares US Aerospace & Defense ETF
ITA
$13.4B
$1.85M 1.03%
7,650
– –
PM icon
25
Philip Morris
PM
$284B
$1.81M 1.01%
10,000
– –
1
2

Similar funds

GPA
Guerra Pan Advisors Montclair, New Jersey $179M AUM 40.97% 1-Year Est. Return
GC
Gould Capital Tacoma, Washington $179M AUM 23.23% 1-Year Est. Return
BRWM
Blue Rock Wealth Management Winston-Salem, North Carolina $179M AUM 24.01% 1-Year Est. Return
IWM
IMG Wealth Management Jacksonville, Florida $180M AUM 21.06% 1-Year Est. Return
BBA
Braun-Bostich & Associates Canonsburg, Pennsylvania $179M AUM 21.93% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $179M AUM
WA
Watchtower Advisors Old Greenwich, Connecticut $180M AUM 81.98% 1-Year Est. Return
CCM
Cox Capital Management Andover, Massachusetts $180M AUM 40.44% 1-Year Est. Return

Knoll Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Knoll Capital Management held 38 positions worth $179M, down 0.48% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Knoll Capital Management deployed $15.1M of net new capital in Q2 2026, opening 1 new position and adding to 4 existing holdings. Its largest new stake was Abivax: 35,000 shares worth $4.66M.

By sector, the portfolio is most concentrated in Materials at 45% of assets, down from 49% a quarter earlier, followed by Healthcare and Miscellaneous.

On the sell side, the most notable exit was Cardiol Therapeutics, an estimated $135K sold.

  • Knoll Capital Management's largest Q2 2026 buy was Abivax: 35,000 shares worth $4.66M.
  • Knoll Capital Management added most to Elicio Therapeutics in Q2 2026, an estimated $5.83M increase.
  • Knoll Capital Management fully exited Cardiol Therapeutics in Q2 2026, selling an estimated $135K.
  • Knoll Capital Management's ten largest holdings make up 59% of its $179M portfolio in Q2 2026.
  • Knoll Capital Management opened 1 new position and closed 1 in Q2 2026.
  • Knoll Capital Management's portfolio value fell 0.48% quarter-over-quarter to $179M.

Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.